The abstract is read at the publisher; the summary is JClub's.
Alectinib produced a centrally confirmed objective response rate of 43.8% in Cohort A (n=16) of patients with advanced ALK-altered solid tumors.
- Why it matters: Prospective evidence for alectinib in tumor-agnostic ALK-altered malignancies beyond lung cancer remains limited, leaving uncertainty about activity and safety across rare tumor types.
- What they did: In this open-label, multicenter phase II TACKLE trial, patients with advanced ALK-altered solid tumors received alectinib, with primary endpoint centrally confirmed RECIST v1.1 ORR using a Bayesian design.
- The result: Among evaluable patients (n=24), ORR was 54.2% and disease control rate was 75.0%, with median progression-free survival of 24.9 months and overall survival of 38.8 months, and grade ≥3 treatment-related adverse events in 15.4% (n=4) without treatment-related deaths.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.